A Recombinant E1-Deleted Canine Adenoviral Vector Capable of Transduction and Expression of a Transgene in Human-Derived Cells and In Vivo
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Human adenovirus (HAV) serotypes 2 and 5 are commonly used as vector backbones for adenovirus-mediated gene transfer. However, HAVs were chosen as a backbone for the vectors for historical reasons and have a number of significant disadvantages when used as a shuttle for gene transfer in humans. As an initial trial to circumvent some of the shortcomings of HAV vectors, we have produced an E1-deleted canine adenovirus type 2 (CAV-2) vector for gene transfer. Initially, we demonstrated that CAV-2 undergoes an abortive viral cycle in a wide range of human-derived cell lines. Second, we assayed human sera containing HAV-5 neutralizing antibodies for their ability to inhibit CAV-2-induced plaques on permissive cells. In the cohort tested, our data demonstrate that the humoral response directed against HAV-5 does not inhibit CAV-2 plaque formation in the majority of cases. Canine cell lines expressing the E1 region of CAV-2 were generated and characterized. A recombinant CAV vector (CAVRSV βgal) deleted in the E1 region and harboring lacZ was constructed. We show that CAVRSV βgal is able to transduce and direct expression of the transgene in vitro in a variety of mammalian cells, most notably primary human-derived cells. In addition, gene transfer is demonstrated in vivo using chick embryos. There are over 100 members of the adenovirus group identified, with 49 belonging to the human type. Human adenoviruses have been the most extensively characterized and were unfortunately chosen as backbones for gene transfer vectors for precisely this reason. For gene transfer in humans, non-human adenoviral vectors eliminate several innate disadvantages of human-derived vectors while retaining most, if not all, of the well-characterized advantages of adenoviral vectors. Our initial efforts with CAV-2 have shown that this non-human vector can infect, and is replication defective in, human-derived cell. An E1-deleted canine adenovirus type 2 vector containing lacZ was able to direct expression of the transgene in human cells and non-human cells in vitro. In addition, ~104 transduction units of CAVRSV βgal were able to transduce a wide variety of cell types in 2-day-old chick embryos.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Packaging capacity and stability of human adenovirus type 5 vectors
Bett, A. J., Prevec, L., & Graham, F. L. (1993) · Journal of Virology · doi:10.1128/jvi.67.10.5911-5921.1993 · Cited by 472 · cited 1×
“As with most viral vectors, the ability to add exogenous D NA to tiie viral backbone is limited by the size of tiie capsid H A V-2 and -5-based vectors can efficienfly package up to 105% of the wild-type genome without substantial rearrangement or deletion (Bett et al, 1993).”
Cited by
Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy
Jooss, K., & Chirmule, N. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302037 · Cited by 277
Adenoviral Vector Immunity: Its Implications and Circumvention Strategies
S. Ahi, Y., S. Bangari, D., & K. Mittal, S. (2011) · Current Gene Therapy · doi:10.2174/156652311796150372 · Cited by 185
Adenovirus vector-based vaccine for infectious diseases
Sakurai, F., Tachibana, M., & Mizuguchi, H. (2022) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2021.100432 · Cited by 148
Circumventing Antivector Immunity: Potential Use of Nonhuman Adenoviral Vectors
Lopez-Gordo, E., Podgorski, I. I., Downes, N., & Alemany, R. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.228 · Cited by 65
Metadata
- Authors
- Klonjkowski, B., Gilardi-Hebenstreit, P., Hadchouel, J., Randrianarison, V., Boutin, S., Yeh, P., Perricaudet, M., & Kremer, E. J.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 1997-11-20
- Volume
- 8
- Issue
- 17
- Pages
- 2103-2115
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2022507792
- Cited by
- 80
- References
- 1
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.